Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients
| Autor: | Szu-Chun Hsu, Ming Yao, Bor-Sheng Ko, Hsiu-Hsia Lin, Hwei-Fang Tien, Wen-Chien Chou, Shang-Yi Huang, Jih-Luh Tang, Shang-Ju Wu |
|---|---|
| Rok vydání: | 2022 |
| Předmět: |
medicine.medical_specialty
Osteolysis Decorin Gastroenterology Bone Marrow Internal medicine medicine Humans Multiple myeloma biology business.industry General Medicine Plasma cell neoplasm medicine.disease Extracellular Matrix carbohydrates (lipids) Treatment Outcome medicine.anatomical_structure Proteoglycan biology.protein Hepatocyte growth factor Bone marrow Multiple Myeloma business Type I collagen medicine.drug |
| Zdroj: | Journal of the Formosan Medical Association. 121:643-651 |
| ISSN: | 0929-6646 |
| Popis: | BACKGROUND/PURPOSE Decorin is a small leucine-rich proteoglycan rich in extracellular matrix with potential antitumor activity. However, the role of decorin in hematological malignancies remains unclear, especially in the case of multiple myeloma (MM), a bone marrow (BM) stroma-dependent plasma cell neoplasm. METHODS We measured decorin levels in BM plasma samples from 270 patients with newly diagnosed MM (NDMM) using enzyme-linked immunosorbent assays. RESULTS Patients were divided into high decorin (H-DCN, > 18.99 ng/mL) and low decorin (L-DCN |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|